Clinical trial NCT04248439: Gene Therapy for Fanconi Anemia, Complementation Group A
Official title: A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Fanconi Anemia Complementation Group A
Keywords: anemia
bone marrow failure
gene therapy
Lead sponsor: Rocket Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2020-01-30
Enrollment: 5
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.

Detailed description: This is a pediatric open-label Phase II clinical trial to assess the efficacy of a hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with FA-A.

Enriched CD34+ hematopoietic stem cells will be transduced ex vivo with the therapeutic lentiviral vector and infused via intravenous infusion following transduction without any prior conditioning.

Eligibility criteria: Inclusion Criteria:

1. Fanconi anemia as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
2. Subject of the complementation group FA-A
3. Minimum age: 1 year and a minimum weight of 8 kg
4. At least 30 CD34+ cells/μL are determined in one bone marrow (BM) aspiration within 3 months prior to CD34+ cell collection OR

6. Provide informed consent in accordance with current legislation 7. Women of childbearing age must have a negative urine pregnancy test at the baseline visit, and accept the use of an effective contraception method during participation in the trial

Exclusion Criteria:

1. Subjects with an available and medically eligible HLA-identical sibling donor.
2. Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the subject commences the stem cell mobilization/collection procedures of the clinical trial.
3. Subjects with somatic mosaicism associated with stable or improved counts in all PB cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease (≥1 NCI CTCAE grade) in at least one blood lineage over time must be documented to enable eligibility, as should \<5% resistance of bone marrow colony forming cells (CFCs) to 10nM MMC; whenever possible potential mosaicism should also be evaluated by gene sequencing of MMC-resistant CFCs).
4. Lansky performance status ≤60%.
5. Any concomitant disease or condition that, in the opinion of the Principal Investigator, renders the subject unfit to participate in the study.
6. Pre-existing sensory or motor impairment ≥grade 2 according to the criteria of the NCI.
7. Pregnant or breastfeeding women.
8. Hepatic dysfunction as defined by either:

   * Bilirubin \>3.0 × the upper limit of normal (ULN) or
   * Alanine aminotransferase (ALT) \> 5.0 × ULN or
   * Aspartate aminotransferase (AST) \> 5.0 × ULN

   For subjects with bilirubin, ALT or AST above ULN, a workup to identify the etiology of liver abnormality should be conducted prior to confirmation of eligibility as stipulated in exclusion criterion 5, including evaluation of viral hepatitis, iron overload, drug injury or other causes.
9. Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
10. Pulmonary dysfunction as defined by either:

    * Need for supplemental oxygen during the prior 2 weeks in absence of acute infection or
    * Oxygen saturation by pulse oximetry \<90%.
11. Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years.
12. Subject is receiving androgens (i.e. danazol, oxymetholone).
13. Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure.

Primary outcomes:
measure: Bone Marrow (BM) Colony-Forming Cell (CFC) Mitomycin-C (MMC) resistance
timeFrame: 21 months
Secondary outcomes:
measure: Genetic Correction
timeFrame: 24 months
measure: Hematologic Stability- Hemoglobin
timeFrame: 24 months
measure: Hematologic Stability- Neutrophils
timeFrame: 24 months
measure: Hematologic Stability- Platelets
timeFrame: 24 months
measure: Phenotypic Correction
timeFrame: 24 months
measure: Safety of RP-L102
timeFrame: 3 years
measure: Tolerability of RP-L102
timeFrame: 3 years
measure: Overall survival
timeFrame: 3 years
measure: Bone Marrow Failure Free Survival
timeFrame: 3 years
measure: Hematological Malignancy Free Survival
timeFrame: 3 years
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: Stanford University
name: Rajni Agarwal, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Margaret MacMillan, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References: